Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells
Figure 1
The synergistic anticancer effects of vorinostat and EGCG were measured by cytotoxic and growth inhibition responses. A 3 × 104 aliquot of cells for the cell cytotoxicity assay and 3 × 103 cells for growth inhibition assay were seeded in 96-well plates. RPMI1640 media supplemented 10% FBS was used to asses tumor cell growth inhibition, whereas serum-free media were used for cell cytotoxicity assay. Single agent treatment: (a) and (b), EGCG; (c) and (d), vorinostat. Combined vorinostat and EGCG: (e) and (f). Growth inhibition: (a), (c), and (e). Cell cytotoxicity: (b), (d), and (f). *P < 0.05; **P < 0.01; ***P < 0.001.
